Apitope was set up with initial funding from the Richard Daniels Family and subsequently received support from the Wellcome Trust, Wyvern and the University of Bristol.

From 2009 to 2010, Apitope raised EUR 10 million in a Series A financing led by LRM and Vesalius Biocapital. Additional funding was provided by Fast Forward, the venture arm of the National MS Society, to accelerate promising research discoveries into the development pipeline.

From 2015 to 2017, Apitope raised more than EUR 12.5 million in a Series B financing, led by Wales Life Sciences Fund (managed by Arthurian Life Sciences).